Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06644443
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple MyelomaA Prospective Single-center Single-arm Phase IIIa Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
At present MM is still an incurable disease in general and the vast majority of patients will eventually face disease recurrence or progression Although CAR-T therapy targeting BCMA has shown advantages in the efficacy and safety of MM for MM patients with BCMA negative or BCMA low expression they still relapse after receiving targeted BCMA CAR T-cell therapy and there is a problem of target escape The specific high expression of GPRC5D in multiple myeloma cells makes it possible to combine BCMA and GPRC5D in the treatment of MM This study aims to investigate the safety and efficacy of BCMA-GPRC5D CAR-T therapy in the treatment of relapsed or refractory MM
Detailed Description:
Multiple myeloma MM is a hematological malignant tumor characterized by clonal proliferation of abnormal plasma cells in the bone marrow The incidence of MM is mainly in the middle and old age and the incidence of MM in China has increased in recent years At present MM is still an incurable disease in general and the vast majority of patients will eventually face disease recurrence or progression Recurrent or refractory MM is still a thorny problem in the treatment of MM which is an important factor for the survival of patientsAlthough CAR-T therapy targeting BCMA has shown advantages in the efficacy and safety of MM for MM patients with BCMA negative or BCMA low expression they still relapse after receiving targeted BCMA CAR T-cell therapy and there is a problem of target escape The specific high expression of GPRC5D in multiple myeloma cells makes it possible to combine BCMA and GPRC5D in the treatment of MM This study aims to investigate the safety and efficacy of BCMA-GPRC5D CAR-T therapy in the treatment of relapsed or refractory MM
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None